1. Cephalon, Inc. (11 from 247 patents)

2. Cancer Research Technology Limited (9 from 262 patents)

3. Bristol-myers Squibb Pharma Company (3 from 234 patents)

4. Bristol-myers Squibb Compnay (1 from 3,684 patents)

5. Bristol-myers Squibb Pharma Corporation (1 from 10 patents)

6. Ignyta, Inc. (25 patents)

1. 11766434 - Pyrimidinone derivatives as CDC7 inhibitors

2. 11020396 - Pyrimidinone derivatives as Cdc7 inhibitors

3. 10954251 - Thienopyrimidine inhibitors of atypical protein kinase C

4. 10919896 - Preparation and uses of pyrimidinone derivatives

5. 10632119 - Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor

6. 10414763 - Azaquinazoline inhibitors of atypical protein kinase C

7. 10183950 - Thienopyrimidine inhibitors of atypical protein kinase C

8. 10111872 - Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor

9. 9914730 - Azaquinazoline inhibitors of Atypical protein Kinase C

10. 9896446 - Azaquinazoline inhibitors of atypical protein kinase C

11. 9623026 - Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor

12. 9604994 - Thienopyrimidine inhibitors of atypical protein kinase C

13. 9487529 - Macrocyclic compounds as ALK, FAK and JAK2 inhibitors

14. 9440984 - Pyrrolotriazines as ALK inhibitors

15. 9339502 - Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor